SAM
TOVX icon

Scopus Asset Management’s Theriva Biologics TOVX Stock Holding History

Scopus Asset Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11
Closed -$2.61K – 219
2018
Q3 		$7K Hold
11
– – ﹤0.01% 226
2018
Q2 		$24K Hold
11
– – ﹤0.01% 281
2018
Q1 		$32K Hold
11
– – ﹤0.01% 286
2017
Q4 		$51K Hold
11
– – ﹤0.01% 282
2017
Q3 		$93K Hold
11
– – ﹤0.01% 272
2017
Q2 		$57K Hold
11
– – ﹤0.01% 247
2017
Q1 		$63K Hold
11
– – ﹤0.01% 217
2016
Q4 		$76K Buy
+11
New +$113K ﹤0.01% 186

Other funds holding TOVX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Scopus Asset Management's TOVX Position: Q4 2018 in Review

Scopus Asset Management sold out of Theriva Biologics (TOVX) in Q4 2018, closing a stake of 11 shares — an estimated $2.61K sold.

Scopus Asset Management first reported a position in TOVX in Q4 2016 and held it in 8 quarters. The position peaked at $93K in Q3 2017. 23 funds tracked by Wall St. Rank hold TOVX as of Q4 2018.

  • Scopus Asset Management reported no remaining Theriva Biologics position as of Q4 2018 after selling out during the quarter.
  • Scopus Asset Management sold 11 Theriva Biologics shares in Q4 2018, an estimated $2.61K.
  • Scopus Asset Management first reported a position in Theriva Biologics in Q4 2016 and held it in 8 quarters.
  • Scopus Asset Management's Theriva Biologics position peaked at $93K in Q3 2017.
  • 23 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2018.

Based on Scopus Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.